Case Studies in Advanced Prostate Cancer

William K. Oh, MD, is the Director of Precision Medicine at the Yale Cancer Center, and a Professor of Medicine for the Division of Medical Oncology at Yale School of Medicine in New Haven, Connecticut. Dr. Oh also serves as Medical Director for the Service Line at Smilow Cancer Hospital within the Greenwich Hospital. Dr. Oh’s specialties include the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers. Dr. Oh’s research interests include novel biomarkers and therapeutics in advanced prostate cancer. 

Dr. Oh received his medical degree from New York University School of Medicine in New York, New York. He completed his internship and residency in Internal Medicine at Brigham and Women’s Hospital in Boston, Massachusetts. He then completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. Prior to joining Mount Sinai in 2009, Dr. Oh served as Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. He was also the founding Chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center. 

In addition to serving as the Principal Investigator of multiple clinical trials in prostate cancer, Dr. Oh has developed large clinical databases and specimen repositories for genitourinary cancers at Harvard Medical School and the Dana-Farber Cancer Institute and at Mount Sinai, which have enrolled more than 10,000 patients with prostate, renal, and bladder cancers. Dr. Oh has authored more than 350 articles, reviews, and book chapters on topics relating to prostate, renal, bladder, and testicular cancers. He has edited three books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association, including the Guidelines Committee for Advanced Prostate Cancer. In addition to reviewing for top journals such as The New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr. Oh co-edits “Testicular Cancer” for Up to Date and is Associate Editor of CA: A Cancer Journal for Clinicians. He is a member of the prestigious American Society for Clinical Investigation and has been repeatedly selected as a Top Doctor in New York magazine, Castle Connolly, Best Doctors, and Super Doctors over the past decade. 

Alan H. Bryce, MD, is a medical oncologist and chief clinical officer at City of Hope in Phoenix, Arizona. Dr. Bryce holds an appointment as a professor with the Department of Medical Oncology & Therapeutics Research, with City of Hope, as well as an appointment as a professor of Molecular Medicine at Translational Genomics Research Institute (TGen), which is also part of City of Hope.

Prior to joining City of Hope, Dr. Bryce spent 12 years at the Mayo Clinic in Phoenix, where he served as chair of the Division of Hematology and Medical Oncology, as well as Director of the Mayo Clinic Arizona Comprehensive Cancer Center. Dr. Bryce received his medical degree from the Chicago Medical School, and then completed an internal medicine residency and a hematology and oncology fellowship at the Mayo Clinic in Rochester, Minnesota. During his time at Mayo, Dr. Bryce served as an international co-principal investigator on multiple clinical trials for prostate cancer, with his research focused on cancer genetics, novel therapies and immunotherapeutic approaches.

Dr. Sartor earned his MD from Tulane University School of Medicine in 1982. After training at the University of Pennsylvania and Tulane Medical School, he completed a fellowship at the National Cancer Institute, where he focused on advanced prostate cancer therapies. He held positions at LSU Medical School and LSU Health Sciences Center, directing oncology programs before joining Dana Farber Cancer Institute in 2006. In 2008, he returned to Tulane University as the C. E. and Bernadine Laborde Professor of Cancer Research.

An internationally recognized expert in prostate cancer, Dr. Sartor’s interests have focused broadly on prostate cancer, predominantly in those patients who failed initial therapies. His publications range from genetic studies on prostate cancer to clinical trials involving novel agents. He has been a lead author on two studies pivotal for FDA drug approval in prostate cancer and has been the PI or co-PI on a number of prospective international clinical trials evaluating new therapies for patients with advanced prostate cancer.

Having published over 500 scholarly articles and having served as the past Chairman of the Department of Defense Prostate Integration Panel, Dr. Sartor, in addition to being the C.E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology, is the Medical Oncology Chair of the GU Committee of the NRG, the Assistant Dean for Oncology at Tulane University School of Medicine, the Medical Director of the Tulane Cancer Center, and the Editor-in-Chief of the peer-reviewed journal, Clinical Genitourinary Cancer. In addition, he is currently a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology).